|

QL1706 (bispecific antibody targeting PD-1 and CLTA-4) Clinical Trials

4 actively recruiting trials

Pipeline

Phase 1: 1Phase 2: 2Phase 1/2: 1

Top Sponsors

  • Xijing Hospital1
  • Sun Yat-sen University1
  • Guangzhou Medical University1
  • Fudan University1

Indications

  • Cancer4
  • CTLA41
  • Pemetrexed1
  • Bone and Soft Tissue Tumors1
  • TNBC - Triple-Negative Breast Cancer1

Other4 trials

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
Phase 1
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
Phase 2
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Phase 1/2
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.